Imaging outcomes in cardiovascular clinical trials

Nature Reviews Cardiology

Volumn 6, Issue 8, 2009, Pages 524-531

  Razzouk, Louai ^a   Farkouh, Michael E ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIAGNOSTIC IMAGING; HUMAN; REVIEW;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DIAGNOSTIC IMAGING; HUMANS;

EID: 70350443110     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2009.104     Document Type: Article

References (58)

1. US Department of Health & Human Services. National Institutes of Health Research Portfolio Online Reporting Tool (RePORT): reports, data and analyses of NIH research activities. Estimates of Funding for Various Research, Condition, and Disease Categories (RCDC) [online], http://report.nih.gov/rcdc/categories (2009).
2. Davies, M. J.; Acute coronary thrombosis—the role of plaque disruption and its initiation and prevention. Eur. Heart J. 16 (Suppl. L), 3-7 (1995).
3. Davies, M. J. Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995. Circulation 94, 2013-2020 (1996).
4. Waters, D., Craven, T. E. & Lesperance, J. Prognostic significance of progression of coronary atherosclerosis. Circulation 87, 1067–1075 (1993).
5. Berry, C. et al. Comparison of intravascular ultrasound and quantitative coronary angiography for the assessment of coronary artery disease progression. Circulation 115, 1851–1857 (2007).
6. O’Leary, D. H. et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N. Engl. J. Med. 340, 14–22 (1999).
7. Bots, M. L. et al. Common carotid intima–media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation 96, 1432–1437 (1997).
8. Hodis, H. N. et al. The role of carotid arterial intima–media thickness in predicting clinical coronary events. Ann. Intern. Med. 128, 262–269 (1998).
9. Tang, T. Y. et al. Correlation of carotid atheromatous plaque inflammation with biomechanical stress: utility of USPIO enhanced MRimaging and finite element analysis. Atherosclerosis 196, 879–887 (2008).
10. Trivedi, R. A. et al. In vivo detection of macrophages in human carotid atheroma: temporal dependence of ultrasmall superparamagnetic particles of iron oxide-enhanced MRI. Stroke 35, 1631-1635 (2004).
11. Amirbekian, V. et al. Detecting and assessing macrophages in vivo to evaluate atherosclerosis noninvasively using molecular MRI. Proc. Natl Acad. Sci. USA 104, 961–966 (2007).
12. Hoffmann, U. et al. Noninvasive assessment of plaque morphology and composition in culprit and stable lesions in acute coronary syndrome and stable lesions in stable angina by multidetector computed tomography. J. Am. Coll. Cardiol. 47, 1655-1662 (2006).
13. Hyafil, F. et al. Noninvasive detection of macrophages using a nanoparticulate contrast agent for computed tomography. Nat. Med. 13, 636-641 (2007).
14. Wayhs, R. et al. High coronary artery calcium scores pose an extremely elevated risk for hardevents. J. Am. Coll. Cardiol. 39, 225-230 (2002).
15. Pohle, K. et al. Characterization of non-calcified coronary atherosclerotic plaque by multi-detector row CT: comparison to IVUS. Atherosclerosis 190, 174-180 (2007).
16. Carrascosa, P. M. et al. Characterization of coronary atherosclerotic plaques by multidetector computed tomography. Am. J. Cardiol. 97, 598-602 (2006).
17. Chen, B. X. et al. Neointimal coverage of bare-metal and sirolimus-eluting stents evaluated with optical coherence tomography. Heart 94, 566-570 (2008).
18. Wang, J. et al. Near-infrared spectroscopic characterization of human advanced atherosclerotic plaques. J. Am. Coll. Cardiol. 39, 1305-1313 (2002).
19. Moreno, P. et al. Detection of lipid pool, thin fibrous cap, and inflammatory cells in human aortic atherosclerotic plaques by near-infrared spectroscopy. Circulation 105, 923-927 (2002).
20. Weber, W. A. & Figlin, R. Monitoring cancer treatment with PET/CT: does it make a difference? J. Nucl. Med. 48 (Suppl. 1), 36S-44S(2007).
21. Ishino, S. et al. 99mTc-annexin A5 for noninvasive characterization of atherosclerotic lesions: imaging and histological studies in myocardial infarction-prone Watanabe heritable hyperlipidemic rabbits. Eur. J. Nucl. Med. Mol. Imaging 34, 889-899 (2007).
22. Johnson, L. L. et al. 99mTc-annexin Vimaging for in vivo detection of atherosclerotic lesions in porcine coronary arteries. J. Nucl. Med. 46, 1186-1193 (2005).
23. Isobe, S. et al. Noninvasive imaging of atherosclerotic lesions in apolipoprotein E-deficient and low-density-lipoprotein receptor-deficient mice with annexin A5. J. Nucl. Med. 47, 1497-1505 (2006).
24. Kietselaer, B. L. et al. Noninvasive detection of plaque instability with use of radiolabeled annexin A5 in patients with carotid-artery atherosclerosis. N. Engl. J. Med. 350, 1472-1473 (2004).
25. Virmani, R., Ladich, E. R., Burke, A. P. & Kolodgie, F. D. Histopathology of carotid atherosclerotic disease. Neurosurgery 59 (Suppl. 3), S219-S227 (2006).
26. Yusuf, S. et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 342, 145-153 (2000).
27. Lonn, E. et al. Effects of ramipril and vitamin Eon atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E(SECURE). Circulation 103, 919-925 (2001).
28. Crouse, J. R. 3rd, Craven, T. E., Hagaman, A. P. & Bond, M. G. Association of coronary disease with segment-specific intimal–medial thickening of the extracranial carotid artery. Circulation 92, 1141-1147 (1995).
29. Espeland, M. A. et al. Reliability of longitudinal ultrasonographic measurements of carotid intimal–medial thicknesses. Asymptomatic Carotid Artery Progression Study Research Group. Stroke 27, 480-485 (1996).
30. Yusuf, S. et al. Vitamin Esupplementation and cardiovascular events in high-risk patients. N. Engl. J. Med. 342, 154-160 (2000).
31. Chen, Z. et al. Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL. Arterioscler. Thromb. Vasc. Biol. 21, 372-377 (2001).
32. Brown, J. D. & Plutzky, J. Peroxisome proliferator activated receptors as transcriptional nodal points and therapeutic targets. Circulation 115, 518-533 (2007).
33. Dormandy, J. A. et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (Prospective Pioglitazone Clinical Trial in Macrovascular Events): a randomised controlled trial. Lancet 366, 1279-1289 (2005).
34. Nissen, S. E. et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPErandomized controlled trial. JAMA 299, 1561-1573 (2008).
35. Langenfeld, M. R. et al. Pioglitazone decreases carotid intima–media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study. Circulation 111, 2525-2531 (2005).
36. Ratner, R. E. et al. Assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history (APPROACH): study design and baseline characteristics. Am. Heart J. 156, 1074-1079 (2008).
37. Cannon, C. P. et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. 350, 1495-1504 (2004).
38. Nissen, S. E. et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291, 1071-1080 (2004).
39. Taylor, A. J. et al. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation 106, 2055-2060 (2002).
40. Ridker, P. M. et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 359, 2195-2207 (2008).
41. Nissen, S. E. et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 295, 1556-1565 (2006).
42. Crouse, J. R. 3rd et al. Effect of rosuvastatin on progression of carotid intima–media thickness in low-risk individuals with subclinical atherosclerosis: the METEORTrial. JAMA 297, 1344-1353 (2007).
43. Kastelein, J. J. et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N. Engl. J. Med. 358, 1431-1443 (2008).
44. Tardif, J. C. et al. Effects of the acyl coenzyme A:cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions. Circulation 110, 3372-3377 (2004).
45. Nissen, S. E. et al. Effect of ACAT inhibition on the progression of coronary atherosclerosis. N. Engl. J. Med. 354, 1253-1263 (2006).
46. Meuwese, M. C. et al. ACAT inhibition and progression of carotid atherosclerosis in patients with familial hypercholesterolemia: the CAPTIVATErandomized trial. JAMA 301, 1131-1139 (2009).
47. Kastelein, J. J. et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N. Engl. J. Med. 356, 1620-1630 (2007).
48. Barter, P. J. et al. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357, 2109-2122 (2007).
49. Nissen, S. E. et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N. Engl. J. Med. 356, 1304-1316 (2007).
50. A study of the effect of RO4607381 on atherosclerotic plaque in patients with coronary heart disease ClinicalTrials.gov: a service of the US National Institutes of Health [online], http://clinicaltrials.gov/ct2/show/NCT00655473 (2009).
51. Tardif, J. C. et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 297, 1675–1682 (2007).
52. Nissen, S. E. et al. Effect of recombinant ApoA-IMilano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 290, 2292–2300 (2003).
53. Niacin plus statin to prevent vascular events. ClinicalTrials.gov: a service of the US National Institutes of Health [online]. http://clinicaltrials.gov/ct/show/NCT00120289 (2009).
54. Farkouh, M. E. et al. Design of the Future Revascularization Evaluation in Patients With Diabetes Mellitus: Optimal Management of Multivessel Disease (FREEDOM) Trial. Am. Heart J. 155, 215–223 (2008).
55. Thoenes, M. et al. The effects of extended-release niacin on carotid intimal media thickness, endothelial function and inflammatory markers in patients with the metabolic syndrome. Int. J. Clin. Pract. 61, 1942–1948 (2007).
56. Brown, B. G. et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N. Engl. J. Med. 345, 1583–1592 (2001).
57. Taylor, A. J. et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2. Circulation 110, 3512–3517 (2004).
58. Taylor, A. J. et al. The effect of 24 months of combination statin and extended-release niacin on carotid intima–media thickness: ARBITER3. Curr. Med. Res. Opin. 22, 2243–2250 (2006).